| Literature DB >> 25178314 |
Hans-Peter Müller1, Jan Kassubek, Georg Grön, Reiner Sprengelmeyer, Albert C Ludolph, Stefan Klöppel, Nicola Z Hobbs, Raymund A C Roos, Alexandra Duerr, Sarah J Tabrizi, Michael Orth, Sigurd D Süssmuth, G Bernhard Landwehrmeyer.
Abstract
BACKGROUND: Corrupted gradient directions (GD) in diffusion weighted images may seriously affect reliability of diffusion tensor imaging (DTI)-based comparisons at the group level. In the present study we employed a quality control (QC) algorithm to eliminate corrupted gradient directions from DTI data. We then assessed effects of this procedure on comparisons between Huntington disease (HD) subjects and controls at the group level.Entities:
Mesh:
Year: 2014 PMID: 25178314 PMCID: PMC4162922 DOI: 10.1186/1475-925X-13-128
Source DB: PubMed Journal: Biomed Eng Online ISSN: 1475-925X Impact factor: 2.819
Figure 1Analysis schemes for cross-sectional comparison. (A) Schematic example for an iterative template-specific MNI-normalization: after a 1st normalization step based on landmarks, first templates T1 ((b = 0) template and FA-template) were obtained by arithmetic averaging of DTI-data I0. Analyses were performed with or without quality control (QC) and subsequent gradient direction elimination. Subsequently, in an iterative procedure, normalized DTI-data I1 were obtained by non-linear normalization to the previously defined templates (T1). From these newly normalized DTI-data I1, new templates (T2) were derived which again could be used for normalization. This iterative process is stopped when a predefined coincidence (measure by correlation) between DTI-data and templates was reached. (B) Scheme for whole brain-based spatial statistics: FA-maps are calculated from normalized DTI data and a smoothing filter to the individual normalized FA-maps is applied. In a consecutive step, voxelwise statistical comparison between the patient groups and the corresponding control group is performed. Final steps are correction for multiple comparisons using the false-discovery-rate (FDR) algorithm and a clustering procedure for further reduction of type I and type II errors.
Figure 2Corrupted slices in DTI volumes. DTI data (volumes number 29 to 31) of an HD subject (subject 589). Upper panel: reconstructed central sagittal slice where axial slices affected by noise are visible (volume number 30). Lower panel: With a QC-threshold of Q = 0.8, nine gradient directions (GD) were detected as corrupted by noise.
Figure 3Region of interest analysis of FA maps from three longitudinal DTI scans. Region of interest (ROI) analysis of visit 1 and visit 3 were without gradient direction (GD) elimination by quality control (QC) since no corruption was evident. During visit 2, 9 GD (compare Figure 1) had to be eliminated. ROI based mean FA values changed with and without QC, respectively. Although ROI localization was identical for the three visits the respective slices look apparently different due to different slice orientation during acquisition.
Figure 4Quality control statistics. Gradient direction (GD) elimination statistics per each visit displays the number of gradient directions excluded in the QC process separately for each subject and for each of the diagnostic groups.
Figure 5Results of cross-sectional group comparison. Clusters of significant FA differences between HD subjects and controls for the three visits. Hot colors indicate FA reductions in the comparison controls vs. HD subjects, cold colors indicate FA increases in this comparison. (A) Representative slices of identical MNI coordinates (0/-29/0) for visits 1 to 3 with and without quality control (QC), respectively. Red circles indicate additional clusters depending if QC based gradient direction elimination was performed, or not. (B) Examples of clusters that are only present in one visit, depending if QC based gradient direction elimination was performed or not. An example is shown for each visit 1 to 3; for clarity of presentation, the respective slices of the other visits for which no clusters could be detected are not displayed.
Cluster statistics for cross-sectional group comparison
| cl. | Visit 1 | Visit 2 | Visit 3 | Visit 1 (QC) | Visit 2 (QC) | Visit 3 (QC) | ||
|---|---|---|---|---|---|---|---|---|
| 1 | basal ganglia | R | 4,337 | 5,143 | 4,491 | 4,579 | 5,356 | 4,551 |
| MNI (x/y/z) | 20/-6/-2 | 18/-7/-2 | 20/-7/-1 | 21/-6/-2 | 19/-8/-2 | 23/3/3 | ||
| 2 | basal ganglia | L | 3,997 | 2,574 | 2,553 | 4,287 | 2,873 | 2,571 |
| MNI (x/y/z) | −19/-8/-3 | −18/-7/-4 | −25/2/7 | −19/-8/-3 | −25/3/7 | −24/3/6 | ||
| 3 | thalamic region internal capsule | R/L | 40,800 | 1,617 | 84,048 | 7,961 | 1,665 | 5,560 |
| MNI (x/y/z) | 34/-17/-13 | 34/-18/-11 | 35/-19/-12 | 35/-18/-12 | 34/-18/-11 | 35/-18/-12 | ||
| 4 | thalamic region | R | within cl. 3 | within cl. 11 | within cl. 3 | 32,070 | 1,289 | within cl. 11 |
| MNI (x/y/z) | −3/-14/4 | −19/-10/9 | ||||||
| 5 | thalamic region | R | within cl. 3 | within cl. 11 | within cl. 3 | 1,859 | within cl. 11 | within cl. 11 |
| MNI (x/y/z) | 25/4/-13 | |||||||
| 6 | thalamic region | R | 1,072 | within cl. 11 | within cl. 3 | 738 | within cl. 11 | within cl. 11 |
| MNI (x/y/z) | 16/-40/4 | 16/-41/4 | ||||||
| 7 | thalamic region | L | 13,094 | 4,770 | within cl. 3 | 11,640 | 2,743 | 4,622 |
| MNI (x/y/z) | −21/-21/-15 | −20/-22/-13 | −21/-21/-13 | −20/-22/-13 | −23/-21/-11 | |||
| 8 | internal capsule | L | within cl. 7 | 432 | within cl. 3 | within cl. 7 | 335 | within cl. 11 |
| MNI (x/y/z) | 18/-9/12 | 18/-9/12 | ||||||
| 9 | external capsule | L | within cl. 7 | within cl. 11 | within cl. 3 | within cl. 7 | 1,406 | within cl. 11 |
| MNI (x/y/z) | −35/-15/7 | |||||||
| 10 | external capsule | R | 255 | within cl. 11 | within cl. 3 | 272 | within cl. 11 | within cl. 11 |
| MNI (x/y/z) | 36/-13/8 | 34/7/2 | ||||||
| 11 | CC | R/L | 1,400 | 41,508 | within cl. 3 | 3426 | 35,008 | 37705 |
| MNI (x/y/z) | −9/18/12 | −11/-25/25 | −7/17/13 | −11/-25/25 | −27/-56/19 | |||
| 12 | occipital lobe | R | 2,210 | 2,026 | 3,166 | 2,160 | 2,015 | 1,845 |
| MNI (x/y/z) | 35/-89/-8 | 38/-74/-5 | 38/-71/-7 | 34/-88/-8 | 38/-75/-4 | 37/-73/-6 | ||
| 13 | occipital lobe | L | 1,685 | 1,027 | within cl. 3 | 2,010 | 950 | 891 |
| MNI (x/y/z) | −40/-68/2 | −39/-69/2 | −41/-68/1 | −39/-69/2 | −40/-67/1 | |||
| 14 | frontal lobe | L | no cluster | 294 | 497 | 373 | 280 | 453 |
| MNI (x/y/z) | −34/27/6 | −41/29/-1 | −40/29/1 | −34/27/6 | −41/29/-1 | |||
| 15 | limbic lobe | L | no cluster | no cluster | within cl. 11 | 296 | 422 | within cl. 11 |
| MNI (x/y/z) | −16/0/37 | −15/3/35 | ||||||
| 16 | parietal lobe | L | 682 | no cluster | within cl. 11 | within cl. 3 | within cl. 11 | within cl. 11 |
| MNI (x/y/z) | −18/-49/34 | |||||||
| 17 | occipital lobe | L | 643 | 319 | within cl. 3 | 283 | 307 | within cl. 13 |
| MNI (x/y/z) | −22/-81/22 | −22/-80/24 | −23/-82/22 | −22/-80/23 | ||||
| 18 | temporal lobe | L | 205 | no cluster | within cl. 3 | 172 | 1279 | 203 |
| MNI (x/y/z) | −46/-52/3 | −47/-50/3 | −48/-53/5 | −46/-51/7 | ||||
| 19 | parietal lobe | R | 230 | no cluster | 311 | 256 | no cluster | 317 |
| MNI (x/y/z) | 19/-64/49 | 19/-61/47 | 19/-62/50 | 18/-63/49 | ||||
| 20 | internal capsule | R/L | 195 | no cluster | no cluster | no cluster | no cluster | no cluster |
| MNI (x/y/z) | −10/6/-6 | |||||||
| 21 | hippocampus | R | 192 | no cluster | no cluster | no cluster | no cluster | no cluster |
| MNI (x/y/z) | L | −26/-20/-26 |
Clusters (cl.) of the FA map group comparison between HD subjects and controls (cl. size/voxels and MNI coordinates of the area with highest significance). All clusters listed in this table show a p-value of p < 0.001. Basically, several cluster groups that are interconnected in different analyses were found. Clusters 1,2 (FA increase): clusters located in the basal ganglia. Clusters 3-17 (FA reduction): clusters covering the thalamic area, external and internal capsule, and corpus callosum (CC); additional clusters in the occipital, frontal, parietal lobe, and limbic regions. Clusters 18-21 (FA reduction): small clusters in the temporal and parietal lobe, the internal capsule, and the hippocampus.